COMPASS THERAPEUTICS (CMPX)
Health Care · Clinical-stage immuno-oncology biopharmaceuticals · NASDAQ
Clinical-stage biotech company developing proprietary bispecific and agonistic antibodies targeting angiogenesis, immune checkpoints, and tumor microenvironment for solid tumor cancers.
What COMPASS THERAPEUTICS does
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human cancers. The company focuses on targeting relationships between angiogenesis, the immune system, and tumor growth through a pipeline of bispecific and agonistic antibodies designed to modulate the microvasculature, induce potent immune responses, and relieve immunosuppressive mechanisms in the tumor microenvironment. The company currently has four clinical product candidates in development, with its lead program (tovecimig/CTX-009) targeting DLL4 and VEGF-A in biliary tract cancer and other solid tumors.
Themes: ["immuno-oncology / checkpoint inhibitors","bispecific antibodies","angiogenesis inhibition","cancer immunotherapy","tumor microenvironment"]
Fundamentals
- Price$2.31 as of 2026-07-09 close
- Market cap$416M as of 2026-07-10
- 1-year return-11.7% as of 2026-07-09 close
- Net margin-5808.8% as of 2026-07-10
- ROE-29.9% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta0.84 as of 2026-07-10
Key risks (from latest filing)
["Clinical-stage development risk: all four product candidates remain in clinical trials with uncertain outcomes and regulatory approval timelines, and failure in Phase 2/3 trials could derail commercialization plans.","Limited cash runway: the company had ~$55M in cash as of March 31, 2026, with quarterly operating burn of ~$20M, limiting ability to fund clinical programs without additional financing.","Competitive landscape: the immuno-oncology and cancer therapy space is crowded with established competitors (Merck, Roche, Bristol Myers Squibb) with approved checkpoint inhibitors and combination therapies, creating significant commercialization risk."]
Competitors & peers
- Merck (MRK)
- Bristol Myers Squibb (BMY)
- Regeneron Pharmaceuticals (REGN)
- Moderna (MRNA)
- Alnylam Pharmaceuticals (ALNY)
- Surface Oncology
- Jounce Therapeutics
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.